哮喘创新药本瑞利珠单抗纳入2025版国家医保目录

环球网
Dec 07, 2025

12月7日,国家医疗保障局、人力资源社会保障部于今日公布了《国家基本医疗保险、工伤保险和生育保险药品目录(2025年)》(以下简称“2025国家医保药品目录”)。2025年国家医保药品目录成功新增114种药品,阿斯利康呼吸领域首款生物制剂凡舒卓(通用名:本瑞利珠单抗注射液)纳入本次医保目录,为成人和12岁及以上青少年重度嗜酸粒细胞性哮喘(SEA)的维持治疗提供了可及的创新治疗方案,有望减轻患者长期...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10